News | May 28, 2007

Study to Probe Adoption Variables in Atrial Fibrillation Therapy

May 29, 2007 — Frost & Sullivan is launching a new end user study on the state of adoption for atrial fibrillation therapies in the U.S. cardiovascular market. Through more than 150 detailed interviews with electrophysiologists, cardiologists and other cardiovascular professionals, the company aims to elucidate key drivers and obstacles to adoption and utilization of various atrial fibrillation treatments.

"Currently no ablation system to date has been approved explicitly for use in treating atrial fibrillation," notes Frost & Sullivan Industry Analyst Venkat Rajan. "However, advancements in 3-D mapping, other imaging techniques, and features within the systems themselves are enabling higher success rates for procedures. Thereby expanding confidence among end users, and gathering enough clinical data for possible FDA approval."

While there are numerous medical device therapies that are being used to treat atrial fibrillation, such as minimally invasive surgical ablation, catheter ablation, open heart surgery ablation, pacemakers, anticoagulants, etc., physician awareness and preference are often the primary determinants of the method used.

"There are a vast number of participants in the market from start-ups and entrepreneurial-type companies to nearly every major cardiovascular device manufacturer," explains Rajan. "Each manufacturer seems to be attempting to carve out their own niche in the market, whether it is through energy modality, or navigational capabilities."

"Manufacturers that can better understand the drivers and obstacles of adoption and utilization preferences for atrial fibrillation device therapies can develop and refine their technologies to best serve customer demand," says Rajan. "With effective third party information partners, companies can take steps to ensure their continued success."

For more information, visit www.frost.com.

Related Content

Computer Simulations May Treat Most Common Heart Rhythm Disorder

The OPTIMA (Optimal Target Identification via Modelling of Arrhythmogenesis) simulator uses contrast-enhanced MRI scans to create personalized digital replicas of a patient's heart to guide catheter abation for atrial fibrillation. Image courtesy of Patrick M. Boyle and Natalia A. Trayanova.

News | EP Mapping and Imaging Systems | August 19, 2019
Scientists at Johns Hopkins have successfully created personalized digital replicas of the upper chambers of the heart...
Charge Density Mapping Eliminates Repeat Ablation for Atrial Fibrillation at One Year
News | EP Mapping and Imaging Systems | July 15, 2019
Acutus Medical announced the publication of the UNCOVER AF study in Circulation: Arrhythmia and Electrophysiology. The...
Innovative Health Receives FDA Clearance to Reprocess Pentaray Nav Eco High-density Mapping Catheter
News | EP Mapping and Imaging Systems | July 05, 2019
Single-use cardiology medical device reprocessing company Innovative Health, received U.S. Food and Drug Administration...
VIVO 3-D Cardiac Mapping System Cleared by FDA
Technology | EP Mapping and Imaging Systems | July 01, 2019
Catheter Precision Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its new VIVO (View into...
Algorithm Steers Catheters to Right Spot to Treat Atrial Fibrillation

Using human AFib simulations, the researchers demonstrated that their technique can stop the catheter at the right target and identify the source type with a 95.25 percent success rate. This new algorithm also is effective in scarred tissue, which makes ablation more challenging, and has a 99 percent detection rate regardless of the scar size. Image courtesy of Florida Atlantic University.

News | EP Mapping and Imaging Systems | May 28, 2019
Researchers have developed the first algorithm that can locate patient-specific ablation targets for atrial...
Acutus Medical Announces Rhythm Xience Acquisition, New Partnerships at HRS 2019

Acutus Medical's acquisition of Rhythm Xience brings the Flextra steerable introducer sheath into Acutus Medical's product portfolio.

News | EP Mapping and Imaging Systems | May 17, 2019
At the 40th annual Heart Rhythm Scientific Sessions, May 8-11 in San Francisco, Acutus Medical announced the agreement...
Electromechanical Wave Imaging (EWI) is a new, high-frame rate 3-D rendered ultrasound technique that can noninvasively map the electromechanical activation of heart rhythm. This example shows the ECG tracings compared to the EWI image of the heart.

Electromechanical Wave Imaging (EWI) is a new, high-frame rate 3-D rendered ultrasound technique that can noninvasively map the electromechanical activation of heart rhythm. This example shows the ECG tracings compared to the EWI image of the heart.

Feature | EP Mapping and Imaging Systems | May 15, 2019 | Dave Fornell, Editor
May 15, 2019 — A new study shows electromechanical wave imaging is capable of localizing arrhythmias including atrial
Philips and Medtronic Collaborate on Image-guided Atrial Fibrillation Treatment
News | EP Mapping and Imaging Systems | May 09, 2019
Philips announced a collaboration with Medtronic to further advance treatment of paroxysmal atrial fibrillation (PAF),...
Acutus Medical Receives FDA Clearance for Second-generation AcQMap Platform
Technology | EP Mapping and Imaging Systems | April 26, 2019
Acutus Medical announced U.S. Food and Drug Administration (FDA) clearance of its second-generation AcQMap platform,...
Acutus AcQMap Imaging System Helps Eliminate Arrhythmia With Single Ablation
News | EP Mapping and Imaging Systems | January 28, 2019
Acutus Medical announced 12-month data from the UNCOVER-AF trial investigating the use of the AcQMap advanced cardiac...
Overlay Init